HALO - Halozyme Therapeutics releases FY21 outlook ahead of JMP healthcare conference stock -6%

Halozyme Therapeutics ([[HALO]] -5.7%) expects its FY21 revenue to range between $375-$395M (+40% to +45% Y/Y), shy of market consensus of $401.22M.The company expects a doubling in revenue from royalties, a significant increase in product sales related to API; however, this guidance excludes any potential new ENHANZE deals.GAAP EPS to be $1.40 to $1.55 (+55% to +70% Y/Y)."In 2021 we expect continued strong revenue and earnings growth driven by continued uptake of subcutaneous DARZALEX® in US and international markets and by uptake of Roche's Phesgo®, which received approval from the European Commission in late December 2020.  In addition, we expect to create catalysts for growth well into the future based on the advancement of multiple partners' ENHANZE® drug development programs," says president and CEO Dr. Helen Torley.The company is scheduled to present at 9th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 3:40 PM ET.#JPM21Now Read: Pfizer/BioNTech can respond within weeks to a new COVID-19 strain

For further details see:

Halozyme Therapeutics releases FY21 outlook ahead of JMP healthcare conference, stock -6%